(Q36458393)

14 August 2017

1 reference

title

Tuberculosis vaccines: current status and future prospects (English)

1 reference

14 August 2017

1 reference

Helen Fletcher

1

0 references

Helen McShane

series ordinal

2

object named as

Helen McShane

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Emerging Drugs

14 August 2017

published in

1 reference

14 August 2017

volume

11

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

207-215

1 reference

The global tuberculosis situation and the new control strategy of the World Health Organization

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Accelerated course of human immunodeficiency virus infection after tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Cost effectiveness analysis of strategies for tuberculosis control in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Comparative genomics of BCG vaccines by whole-genome DNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

The reinfection threshold promotes variability in tuberculosis epidemiology and vaccine efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

How can immunology contribute to the control of tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Immunogenicity and protective efficacy of a tuberculosis DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Vaccination against tuberculosis by DNA injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Animal models of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Preclinical testing of new vaccines for tuberculosis: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

A mouse model of the recrudescence of latent tuberculosis in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Tuberculosis vaccine development: research, regulatory and clinical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Florid pulmonary inflammatory responses in mice vaccinated with Antigen-85 pulsed dendritic cells and challenged by aerosol with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Skin test performed with highly purified Mycobacterium tuberculosis recombinant protein triggers tuberculin shock in infected guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

New TB vaccine granted orphan drug status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Therapy of tuberculosis in mice by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Mycobacteria induce CD4+ T cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

Safety issues regarding new vaccines for tuberculosis, with an emphasis on post-exposure vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.207

10.1517/14728214.11.2.207

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference